A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04322292
• Other study ID #: QT-2019007-EC-2
• Status: Recruiting
• Phase: Phase 1
• Start date: September 12, 2019
• Est. completion date: November 2021

Study information

• Verified date: March 2020
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Gang An, PhD&MD
• Phone: 008613502181109
• Email: angang[@]ihcams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

Description:

The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: November 2021
• Est. primary completion date: August 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 18-75 years old, male or female;

2. The patient volunteered to participate in the study, and he or his legal guardian signed the Informed Consent;

3. Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG diagnostic criteria 2014);

4. Patients with a clear diagnosis of relapsed or refractory multiple myeloma who have received at least 3 lines of MM (Contains proteasome inhibitors and immunomodulatory therapies that progress or relapse during the most recent treatment or after the end of treatment). Note: The planned treatment plan for one or more cycles is "one-line treatment"; induction chemotherapy, stem cell transplantation, and maintenance treatment (if there is no disease progression between them), it is considered as a one-line treatment plan;

5. The patient have one or more measurable multiple myeloma lesion, must include one of the following conditions:

• Serum M protein=1.0 g/dL(10g/L)

• Urine M protein=200 mg/24h

• Serum free light chain(sFLC): ?/? FLC ratio is abnormal and affected FLC =10mg / dL

6. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination;

7. ECOG scores 0 - 1;

8. Echocardiography showed normal diastolic function, left ventricular ejection fraction (LVEF) =50%, and no severe arrhythmia;

9. No active pulmonary infections, normal pulmonary function and oxygen saturation = 92% on room air.

10. Absolute neutrophil count =1.0 × 109 / L, platelet count =50 × 109 / L; total serum bilirubin =1.5mg / dl; serum ALT or AST less than 2.5 times the upper limit of normal; serum creatinine =2.0mg / dl;

11. No contraindications of peripheral blood apheresis;

12. Expected survival time > 12 weeks;.

13. Female subjects of childbearing age must have a negative urine / blood pregnancy test within 7 days before cell therapy and not be in lactation; female or male subjects of childbearing age need to take effective contraception throughout the study.

Exclusion Criteria:

1. Have a history of allergy to cell ular products;

2. Presence of clinically significant cardiovascular disease, such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or any heart function Grade 3 (moderate) or Grade 4 (severe) heart disease (according to the New York Heart Association Function Classification method: NYHA); patients with a history of myocardial infarction, cardiac angioplasty or stent implantation, unstable angina pectoris or other clinically significant heart disease within 12 months before enrollment;

3. A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral ischemia or hemorrhagic disease;

4. Need to use any anticoagulant (except aspirin);

5. Patients requiring urgent treatment due to tumor progression or spinal cord compression;

6. Patients with CNS metastasis or symptoms of CNS involvement;

7. After allogeneic hematopoietic stem cell transplantation;

8. Plasma cell leukemia;

9. Received systemic anti-tumor treatment within 2 weeks before apheresis, and within 1 week before apheresis, prednisone (or equivalent amount of other corticosteroids) was applied in excess of 5 mg/d ;

10. Patients with autoimmune diseases, immunodeficiency, or other immunosuppressive agents;

11. Uncontrolled active infection;

12. Have used any CAR T cell products or other genetically modified T cell therapy before;

13. Live vaccination within 4 weeks before enrollment;

14. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV infected persons;

15. Have a history of alcoholism, drug addiction and mental illness;

16. Participated in any other clinical trial within 1 months;

17. The investigators believe that there are other circumstances that are not suitable for the trial.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• C-CAR088
Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10^6 anti-BCMA CAR+T cells/kg. Divided into three dose ranges of low(1.0-3.0×10^6 CAR+T cells/kg),medium(3.0-6.0×10^6 CAR+T cells/kg) and high(6.0-9.0×10^6 CAR+T cells/kg). Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.

Locations

Country	Name	City	State
China	InstituteHBDH	TianJin

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: The incidence of treatment-emergent adverse events (TEAEs)	The incidence of treatment-emergent adverse events (TEAEs)	30 days
Secondary	Overall response rate (ORR)	ORR(including sCR / CR / VGPR / PR, based on IMWG 2016 efficacy evaluation criteria)	12 months
Secondary	Progression free survival (PFS)	PFS(based on IMWG 2016 efficacy evaluation criteria)	6 months?12 months
Secondary	The CART cell duration in vivo	The copys of BCMA-CART DNA in peripheral blood with qPCR method	12 months
Secondary	The soluble BCMA changes in peripheral blood	The amount of soluble BCMA in peripheral blood with ELISA method	12 months